PE20160284A1 - Derivados de amida como antogonistas del receptor de acido lisofosfatidico - Google Patents
Derivados de amida como antogonistas del receptor de acido lisofosfatidicoInfo
- Publication number
- PE20160284A1 PE20160284A1 PE2016000269A PE2016000269A PE20160284A1 PE 20160284 A1 PE20160284 A1 PE 20160284A1 PE 2016000269 A PE2016000269 A PE 2016000269A PE 2016000269 A PE2016000269 A PE 2016000269A PE 20160284 A1 PE20160284 A1 PE 20160284A1
- Authority
- PE
- Peru
- Prior art keywords
- halogen
- methyl
- antogonists
- acid receptor
- amide derivatives
- Prior art date
Links
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 title 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 title 1
- 150000001408 amides Chemical class 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 125000000172 C5-C10 aryl group Chemical group 0.000 abstract 1
- SFLFAQAYQIAVDW-UHFFFAOYSA-N CCN(Cc1ccc(cc1)C(O)=O)C(=O)c1ccc(Oc2ccccc2F)cc1 Chemical compound CCN(Cc1ccc(cc1)C(O)=O)C(=O)c1ccc(Oc2ccccc2F)cc1 SFLFAQAYQIAVDW-UHFFFAOYSA-N 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 101001038037 Homo sapiens Lysophosphatidic acid receptor 5 Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102100040404 Lysophosphatidic acid receptor 5 Human genes 0.000 abstract 1
- KARVIVULTZYCNP-UHFFFAOYSA-N OC(=O)c1ccc(CN(CC(F)F)C(=O)c2ccc(Oc3ccccc3F)cc2)cc1 Chemical compound OC(=O)c1ccc(CN(CC(F)F)C(=O)c2ccc(Oc3ccccc3F)cc2)cc1 KARVIVULTZYCNP-UHFFFAOYSA-N 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1314926.5A GB201314926D0 (en) | 2013-08-20 | 2013-08-20 | Novel Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160284A1 true PE20160284A1 (es) | 2016-04-27 |
Family
ID=49301993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000269A PE20160284A1 (es) | 2013-08-20 | 2014-08-20 | Derivados de amida como antogonistas del receptor de acido lisofosfatidico |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10100018B2 (enExample) |
| EP (1) | EP3036215A1 (enExample) |
| JP (1) | JP6422974B2 (enExample) |
| KR (1) | KR20160045797A (enExample) |
| CN (1) | CN105473548B (enExample) |
| AR (1) | AR097403A1 (enExample) |
| AU (1) | AU2014310404B2 (enExample) |
| CA (1) | CA2921742A1 (enExample) |
| CL (1) | CL2016000387A1 (enExample) |
| CR (1) | CR20160084A (enExample) |
| EA (1) | EA028818B1 (enExample) |
| GB (1) | GB201314926D0 (enExample) |
| HK (1) | HK1225712A1 (enExample) |
| IL (1) | IL243780A0 (enExample) |
| MA (1) | MA38854B1 (enExample) |
| MX (1) | MX2016001896A (enExample) |
| PE (1) | PE20160284A1 (enExample) |
| PH (1) | PH12016500322A1 (enExample) |
| SG (1) | SG11201601250TA (enExample) |
| TN (1) | TN2016000061A1 (enExample) |
| TW (1) | TW201536722A (enExample) |
| UY (1) | UY35708A (enExample) |
| WO (1) | WO2015025164A1 (enExample) |
| ZA (1) | ZA201600753B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201314926D0 (en) | 2013-08-20 | 2013-10-02 | Takeda Pharmaceutical | Novel Compounds |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| TWI836124B (zh) | 2019-07-30 | 2024-03-21 | 日商大正製藥股份有限公司 | 拮抗ｌｐａ１受體之脲化合物 |
| KR102775995B1 (ko) | 2019-11-15 | 2025-03-11 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 |
| JP7591066B2 (ja) | 2020-06-03 | 2024-11-27 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| WO2022240879A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| JP7691522B2 (ja) | 2021-05-13 | 2025-06-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| CA3238094A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2024252334A1 (en) * | 2023-06-06 | 2024-12-12 | Gpcr Therapeutics, Inc. | Gpcr inhibitors and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2707641B1 (fr) * | 1993-07-16 | 1995-08-25 | Fournier Ind & Sante | Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique. |
| EP1229034B1 (en) | 2001-01-31 | 2005-04-13 | Pfizer Products Inc. | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| AU2003241834A1 (en) | 2002-06-26 | 2004-01-19 | Ono Pharmaceutical Co., Ltd. | Remedy for chronic disease |
| WO2004031118A1 (ja) * | 2002-10-03 | 2004-04-15 | Ono Pharmaceutical Co., Ltd. | Ｌｐａ受容体拮抗剤 |
| EP2462128B1 (en) * | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| BR112012006686B8 (pt) | 2009-09-25 | 2021-05-25 | Astellas Pharma Inc | compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| PH12012500542A1 (en) | 2010-09-24 | 2012-11-12 | Astellas Pharma Inc | Substituted amide compound |
| CN103443098B (zh) * | 2011-01-30 | 2016-03-16 | 广州源生医药科技有限公司 | 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用 |
| EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| GB201314926D0 (en) | 2013-08-20 | 2013-10-02 | Takeda Pharmaceutical | Novel Compounds |
-
2013
- 2013-08-20 GB GBGB1314926.5A patent/GB201314926D0/en not_active Ceased
-
2014
- 2014-08-18 TW TW103128316A patent/TW201536722A/zh unknown
- 2014-08-19 UY UY0001035708A patent/UY35708A/es not_active Application Discontinuation
- 2014-08-20 US US14/913,135 patent/US10100018B2/en not_active Expired - Fee Related
- 2014-08-20 JP JP2016535530A patent/JP6422974B2/ja not_active Expired - Fee Related
- 2014-08-20 US US14/463,780 patent/US9464060B2/en not_active Expired - Fee Related
- 2014-08-20 CA CA2921742A patent/CA2921742A1/en not_active Abandoned
- 2014-08-20 WO PCT/GB2014/052558 patent/WO2015025164A1/en not_active Ceased
- 2014-08-20 MA MA38854A patent/MA38854B1/fr unknown
- 2014-08-20 AU AU2014310404A patent/AU2014310404B2/en not_active Expired - Fee Related
- 2014-08-20 HK HK16113982.5A patent/HK1225712A1/zh unknown
- 2014-08-20 EA EA201690390A patent/EA028818B1/ru not_active IP Right Cessation
- 2014-08-20 SG SG11201601250TA patent/SG11201601250TA/en unknown
- 2014-08-20 CN CN201480046178.8A patent/CN105473548B/zh not_active Expired - Fee Related
- 2014-08-20 EP EP14756117.9A patent/EP3036215A1/en not_active Withdrawn
- 2014-08-20 TN TN2016000061A patent/TN2016000061A1/en unknown
- 2014-08-20 PE PE2016000269A patent/PE20160284A1/es not_active Application Discontinuation
- 2014-08-20 KR KR1020167007214A patent/KR20160045797A/ko not_active Withdrawn
- 2014-08-20 MX MX2016001896A patent/MX2016001896A/es unknown
- 2014-08-20 AR ARP140103129A patent/AR097403A1/es unknown
-
2016
- 2016-01-26 IL IL243780A patent/IL243780A0/en unknown
- 2016-02-03 ZA ZA2016/00753A patent/ZA201600753B/en unknown
- 2016-02-18 PH PH12016500322A patent/PH12016500322A1/en unknown
- 2016-02-19 CL CL2016000387A patent/CL2016000387A1/es unknown
- 2016-02-19 CR CR20160084A patent/CR20160084A/es unknown
-
2018
- 2018-08-20 US US15/999,570 patent/US20190010129A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201690390A1 (ru) | 2016-08-31 |
| EA028818B1 (ru) | 2018-01-31 |
| MA38854A1 (fr) | 2017-07-31 |
| CR20160084A (es) | 2016-05-27 |
| TN2016000061A1 (en) | 2017-07-05 |
| US10100018B2 (en) | 2018-10-16 |
| JP2016528274A (ja) | 2016-09-15 |
| TW201536722A (zh) | 2015-10-01 |
| MA38854B1 (fr) | 2018-05-31 |
| AU2014310404A1 (en) | 2016-03-10 |
| PH12016500322A1 (en) | 2016-05-02 |
| SG11201601250TA (en) | 2016-03-30 |
| CN105473548A (zh) | 2016-04-06 |
| KR20160045797A (ko) | 2016-04-27 |
| AR097403A1 (es) | 2016-03-09 |
| CL2016000387A1 (es) | 2016-12-16 |
| JP6422974B2 (ja) | 2018-11-14 |
| HK1225712A1 (zh) | 2017-09-15 |
| AU2014310404B2 (en) | 2018-07-12 |
| GB201314926D0 (en) | 2013-10-02 |
| EP3036215A1 (en) | 2016-06-29 |
| CN105473548B (zh) | 2018-03-23 |
| ZA201600753B (en) | 2019-07-31 |
| US20160207880A1 (en) | 2016-07-21 |
| IL243780A0 (en) | 2016-04-21 |
| WO2015025164A1 (en) | 2015-02-26 |
| US20150057298A1 (en) | 2015-02-26 |
| MX2016001896A (es) | 2016-05-26 |
| US9464060B2 (en) | 2016-10-11 |
| CA2921742A1 (en) | 2015-02-26 |
| US20190010129A1 (en) | 2019-01-10 |
| UY35708A (es) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160284A1 (es) | Derivados de amida como antogonistas del receptor de acido lisofosfatidico | |
| CU20210009A7 (es) | Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3) | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| CO7131358A2 (es) | Compuestos de n-alquiltriazol como antagonistas de lpar | |
| CO7131357A2 (es) | Compuestos de n-ariltriazol como antagonistas de lpar | |
| PE20141726A1 (es) | Heterociclilaminas como inhibidores de pi 3k | |
| PE20151001A1 (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| PE20151428A1 (es) | Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrogeno | |
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| PE20181197A1 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
| PE20142294A1 (es) | Compuestos de indol e indazol que activan la ampk | |
| AR073622A1 (es) | Compuestos de benzo[d]isoxazol moduladores de receptores de dopamina d3 y de la serotonina 5-ht2a, proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos psicoticos | |
| PA8815001A1 (es) | Piridinil amidas para el tratamiento de trastornos del snc y metabolicos | |
| MX2022011354A (es) | Compuestos de pirimidina fusionados como moduladores de kcc2. | |
| CL2017002354A1 (es) | Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. | |
| CO7160077A2 (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
| MX2017016413A (es) | Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem. | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| MX380619B (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| MX2017011978A (es) | Analogos deuterados de etifoxina, sus derivados y usos de estos. | |
| EA201690072A1 (ru) | Состав, содержащий гиполипидемическое средство | |
| MX389378B (es) | Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. | |
| ES2723436T3 (es) | Derivados de pirrolopirimidina como antagonistas del receptor NMDA NR2B | |
| CL2020001140A1 (es) | Compuestos espirocíclicos como moduladores del receptor farnesoide x. | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |